Globenewswire·2025-09-20 13:13Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, alleging misleading statements regarding the company's drug application process [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Savara made false statements about the MOLBREEVI Biologics License Application (BLA), indicating it lacked sufficient information for FDA approval [5]. - It is alleged that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay Savara's submission timeline and increase the need for additional capital [5]. - The lawsuit asserts that these misleading statements caused investors to suffer damages when the true information became public [5]. Group 2: Class Action Participation - Investors who purchased Savara securities during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form online or contact the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 7, 2025, to represent the interests of the class members [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].